Short-term efficacy and safety of guselkumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis with a pasi response-depth analysis

医学 阿达木单抗 随机对照试验 荟萃分析 安慰剂 临床试验 内科学 不利影响 析因分析 银屑病 皮肤病科 单盲板 物理疗法 事后 子群分析 银屑病面积及严重程度指数 斑块性银屑病
作者
Mailidan Maimaitiniyazi,Muyesaier Maimaitiniyazi,Meiheliya Maisuti,Abuduwupuer Haibier,Muyesai Nijiati
出处
期刊:BMC Clinical Pharmacology [BioMed Central]
卷期号:27 (1): 161-
标识
DOI:10.1186/s40360-026-01222-z
摘要

To systematically evaluate the short-term efficacy and safety of guselkumab in moderate-to-severe plaque psoriasis and to explore whether its comparative advantage over adalimumab changes across increasingly stringent PASI response thresholds. PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data were systematically searched from inception to April 2026 for randomized controlled trials (RCTs) evaluating guselkumab in moderate-to-severe plaque psoriasis. Two reviewers independently screened the literature, extracted data, and assessed methodological quality using the Cochrane RoB 2.0 tool. Meta-analysis was performed using RevMan 5.3. All efficacy and safety data were extracted at Week 16. In a post hoc exploratory response-depth analysis of the three head-to-head trials, the relative treatment effect of guselkumab versus adalimumab was examined across PASI75, PASI90, and PASI100 thresholds. Six RCTs comprising 997 patients in the guselkumab group, 625 in the adalimumab group, and 548 in the placebo group were included. At Week 16, guselkumab was associated with a significantly higher PASI90 response rate than adalimumab (RR = 1.48, 95% CI: 1.35–1.62, P < 0.001) and placebo (RR = 28.29, 95% CI: 16.69–47.96, P < 0.001). The exploratory head-to-head response-depth analysis showed a progressive increase in the relative advantage of guselkumab as the PASI target became more stringent: RR = 1.25 (95% CI: 1.18–1.32) for PASI75, 1.48 (1.35–1.62) for PASI90, and 1.85 (1.54–2.23) for PASI100. Corresponding crude response proportions across the three direct-comparison trials were 87.8% versus 71.0%, 70.8% versus 48.2%, and 35.3% versus 19.0%, respectively. Most short-term safety comparisons were imprecise and did not reach statistical significance. For upper respiratory tract infection versus adalimumab, the pooled estimate was RR = 1.69 (95% CI: 0.99–2.87; P = 0.05) based on two trials; the confidence interval only narrowly included the null and the comparison was underpowered. Beyond confirming greater Week 16 efficacy of guselkumab, this meta-analysis suggests that its relative advantage over adalimumab becomes more pronounced as the treatment target shifts from PASI75 toward near-complete or complete skin clearance. This response-depth pattern may be clinically relevant in an era in which PASI90 and PASI100 are increasingly used as treatment goals. Most evaluated short-term safety outcomes did not show statistically significant differences; however, estimates were imprecise and should not be interpreted as evidence of equivalence.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zhengzhi发布了新的文献求助10
1秒前
王亚奇发布了新的文献求助10
2秒前
qianzhihe发布了新的文献求助10
2秒前
Akim的应助被8mian采纳,获得10
2秒前
Maestro_S的应助被冷酷的松思采纳,获得10
2秒前
2秒前
入司的应助被李麟采纳,获得10
2秒前
sk566发布了新的文献求助10
2秒前
3秒前
你快睡吧完成签到,获得积分10
4秒前
科研通AI2S的应助被管某采纳,获得10
5秒前
义气芯完成签到,获得积分10
5秒前
JamesPei的应助被刘泽楷采纳,获得10
6秒前
kkkk发布了新的文献求助10
6秒前
6秒前
pajamsleep完成签到,获得积分10
6秒前
dwink发布了新的文献求助10
7秒前
天天快乐的应助被RobiN采纳,获得10
7秒前
顾矜的应助被8mian采纳,获得10
7秒前
angelcynthia发布了新的文献求助10
7秒前
ding的应助被抽烟酒牲采纳,获得30
7秒前
入司的应助被研友_ZragOn采纳,获得10
8秒前
斯文败类的应助被renyi采纳,获得10
8秒前
8秒前
sw123完成签到,获得积分10
9秒前
汉堡包的应助被楠楠采纳,获得10
9秒前
Lost_Flight完成签到,获得积分10
9秒前
桐桐的应助被有几颗荔枝采纳,获得10
10秒前
假装新疆人烤大串儿完成签到,获得积分10
10秒前
wengi94完成签到,获得积分20
10秒前
开心的灵枫完成签到 ,获得积分10
11秒前
鲤鱼土豆完成签到,获得积分10
12秒前
余泽楷发布了新的文献求助10
12秒前
wujingshuai完成签到,获得积分10
12秒前
冷酷的松思完成签到,获得积分10
12秒前
Owen的应助被科研通管家采纳,获得10
12秒前
情怀的应助被科研通管家采纳,获得10
13秒前
ll完成签到,获得积分10
13秒前
丘比特的应助被科研通管家采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065